Monitoring9 min readUpdated 2025-04-03

    GLP-1 Symptom Diary: Track Side Effects for Better Treatment

    Keep an effective GLP-1 symptom diary to track side effects from semaglutide or tirzepatide. Learn what to record, when to call your doctor, and how to share data with providers.

    Data-Driven Treatment

    A symptom diary transforms vague complaints into actionable data. When you tell your provider "I have nausea on injection day that peaks at 6 hours and resolves by morning," they can adjust your treatment far more effectively than with "I feel sick sometimes."

    What to Record in Your Symptom Diary

    Whether you're taking semaglutide or tirzepatide, systematic symptom tracking helps optimize your treatment plan.

    GI Symptoms

    • Nausea (severity, timing, triggers)
    • Vomiting (frequency, relation to meals)
    • Constipation or diarrhea
    • Bloating, gas, acid reflux

    General Symptoms

    • Headaches (location, intensity)
    • Fatigue or dizziness
    • Injection site reactions
    • Mood changes, sleep disruption

    Symptom Pattern Recognition

    Injection-Day Pattern

    If symptoms peak on injection day and fade within 48 hours, this is the most common pattern. Consider injecting before bed or adjusting injection timing.

    Food-Triggered Pattern

    If symptoms worsen after fatty or large meals, portion control and dietary adjustments may help more than medication changes.

    Constant/Worsening Pattern

    If symptoms persist throughout the week or worsen over time, contact your provider. You may need dose adjustment or additional evaluation.

    When Your Diary Signals Action

    Seek Immediate Medical Attention If You Record:

    • Severe abdominal pain radiating to the back (possible pancreatitis)
    • Persistent vomiting for more than 24 hours
    • Signs of allergic reaction (swelling, difficulty breathing, rash)
    • Neck swelling or lump, difficulty swallowing
    • Signs of severe dehydration (dark urine, rapid heart rate, confusion)

    Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider about side effects and treatment concerns.

    Frequently Asked Questions

    What side effects should I track in my GLP-1 diary?

    Track nausea, vomiting, diarrhea, constipation, headaches, fatigue, injection site reactions, dizziness, bloating, acid reflux, and any other symptoms you experience. Rate severity on a 1-10 scale and note timing relative to your injection.

    How detailed should my symptom diary be?

    Include the date, time, symptom type, severity (1-10), duration, potential triggers (foods, activities), and what helped. Even brief notes are valuable. The goal is identifying patterns, not writing essays.

    When should side effects in my diary concern me?

    Contact your provider if you experience severe vomiting lasting more than 24 hours, signs of pancreatitis (severe abdominal pain radiating to the back), allergic reactions, or any symptoms that significantly impact your daily functioning.

    Do GLP-1 side effects get better over time?

    Yes, most GLP-1 side effects (especially nausea) improve within 4-8 weeks as your body adjusts. Your symptom diary will help you see this trend. Side effects often temporarily increase with dose escalations but improve again.

    Get Expert-Monitored GLP-1 Treatment

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo with ongoing provider support.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What should patients know about GLP-1 side effects?

    Peer-reviewed / regulatory evidence: In STEP 1, the most-reported adverse events with semaglutide 2.4 mg vs placebo were nausea (approximately 44% vs 16%), diarrhea (approximately 32% vs 11%), vomiting (approximately 25% vs 6%), and constipation (approximately 24% vs 11%). Most events were mild-to-moderate and most common during dose escalation. (Source: STEP 1, NEJM 2021). Trimi's clinical-review process — coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network — addresses GLP-1 side effects as part of the individualized patient-care plan. Compounded medications are dispensed by 503A community sterile compounding pharmacies (VialsRx, GreenwichRx). This is general information based on the cited sources, not medical advice.

    In STEP 1, the most-reported adverse events with semaglutide 2.4 mg vs placebo were nausea (approximately 44% vs 16%), diarrhea (approximately 32% vs 11%), vomiting (approximately 25% vs 6%), and constipation (approximately 24% vs 11%). Most events were mild-to-moderate and most common during dose escalation. — STEP 1, NEJM 2021
    In SURMOUNT-1, gastrointestinal adverse events occurred in approximately 81% of tirzepatide 15 mg participants vs 53% of placebo participants over 72 weeks; most resolved with continued therapy and dose adjustment. — SURMOUNT-1, NEJM 2022

    Key Takeaways

    • In STEP 1, the most-reported adverse events with semaglutide 2.4 mg vs placebo were nausea (approximately 44% vs 16%), diarrhea (approximately 32% vs 11%), vomiting (approximately 25% vs 6%), and constipation (approximately 24% vs 11%). Most events were mild-to-moderate and most common during dose escalation. (Source: STEP 1, NEJM 2021)
    • In SURMOUNT-1, gastrointestinal adverse events occurred in approximately 81% of tirzepatide 15 mg participants vs 53% of placebo participants over 72 weeks; most resolved with continued therapy and dose adjustment. (Source: SURMOUNT-1, NEJM 2022)
    • Most GLP-1 adverse events are gastrointestinal (nausea, vomiting, diarrhea, constipation), mild-to-moderate in severity, and concentrated during dose-escalation weeks. Severe or persistent symptoms should be discussed with the prescribing clinician promptly.
    • GLP-1 receptor agonists require a prescription. Eligibility is determined by a licensed clinician based on BMI, weight-related comorbidities, and screening for contraindications (medullary thyroid carcinoma history, MEN 2, pancreatitis history, severe GI / renal disease, pregnancy, breastfeeding).
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: December 29, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. U.S. Food and Drug Administration (2024). Wegovy (semaglutide) Prescribing Information — Adverse Reactions section. FDA.Read Study
    2. U.S. Food and Drug Administration (2024). Zepbound (tirzepatide) Prescribing Information — Adverse Reactions section. FDA.Read Study
    3. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — Safety endpoints. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183

    Was this article helpful?

    Keep Reading

    Learn the best techniques for taking GLP-1 weight loss progress photos. Consistent lighting, angles, and timing help you accurately track semaglutide and tirzepatide results.

    Create a comprehensive monthly GLP-1 progress report. Compile weight trends, side effects, measurements, and lab results to optimize your semaglutide or tirzepatide treatment.

    Know the critical warning signs while on GLP-1 medications. Learn when to call your doctor, visit the ER, or stop semaglutide or tirzepatide. Your safety guide for GLP-1 treatment.

    Use this weekly GLP-1 check-in template to track your semaglutide or tirzepatide progress. Monitor weight, side effects, appetite, energy, and treatment effectiveness.

    Start your GLP-1 journey — from $99/mo

    Get Started